SPARC — Sun Pharma Advanced Research Share News
0.000.00%
Last trade - 00:00- IN₹55.74bn
- IN₹61.31bn
- IN₹391.48m
Brief: Sun Pharma Advanced Research Appoints Anil Raghavan As MD And CEO Effective August 11
Brief: Sun Pharma Advanced Research Says Ocuvex Therapeutics Gets Complete Response Letter For PDP-716 NDA
India's Sun Pharma Advanced Research jumps after swinging to Q4 profit
Brief: Sun Pharma Advanced Research March-Quarter Consol Profit 17.61 Billion Rupees
Brief: Sun Pharma Advanced Research Announces Sale Of Priority Review Voucher For USD 195 Million
Brief: Sun Pharma Advanced Research Receives FDA Priority Review Voucher For Sezaby Approval
Brief: Sun Pharma Advanced Research Says Issue Price 155.80 Rupees Per Warrant
Brief: Sun Pharma Advanced Research Approves Preferential Issue Of Convertible Warrants Of Upto 6 Billion Rupees
Brief: Sun Pharma Advanced Research Says Overall Workforce To Reduce By 40%
India's Sun Pharma Advanced Research rises on favourable summary judgement by US Court
Brief: Sun Pharma Advanced Research Says US Court Grants Summary Judgment In Favor Of Co's Sparc Unit For Sezaby Prv
Brief: Sun Pharma Advanced Research Says US FDA Did Not Raise Concerns On PDP-716 Efficacy Or Safety
India's Sun Pharma Advanced Research slumps 15% after drug fails mid-stage study
Brief: Sun Pharma Advanced Research Co To Consider Fund Raising
Brief: Sun Pharma Advanced Research Co Submits IND Application For SBO-154 To USFDA
Brief: Sun Pharma Advanced Research Signs Binding LOI With UCSF And Tiller Therapeutics
India's Sun Pharma Advanced Research falls after Q2 loss widens
Consumer groups ask FTC to block Novo Holdings-Catalent deal (updated)
Consumer groups ask FTC to block Novo Holdings-Catalent deal